SUMMARY Depression is a common feature of Parkinson's disease, a fact of both clinical and theoretical significance. Assessment of depression in Parkinson's disease is complicated by overlapping symptomatology in the two conditions, making global assessments based on observer or self-ratings of doubtful validity. The present study aimed to provide both a quantitative and qualitative description of the nature of the depressive changes found in Parkinson's disease as compared with normal elderly subjects and arthritis patients. As with previous studies, the patients with Parkinson's disease scored significantly higher than normal controls on various self-ratings of depression and anxiety but, in this study, did not differ from those with arthritis. Qualitatively, both the Parkinson's disease and the arthritis groups had depression characterised by pessimism and hopelessness, decreased motivation and drive, and increased concern with health. In contrast, the negative affective feelings of guilt, self-blame and worthlessness were absent in both patient groups. This pattern of depression was significantly associated with severity of illness and functional disability. However, these factors account for only a modest proportion of the variability in test scores. Probable unexplored factors are individual differences in coping style and availability of support.
The association between Parkinson's disease and depression is known, but the exact prevalence of the depression, its nature and aetiology remain uncertain. This is the result of difficulties both in the methods of studying depression in patients with Parkinson's disease, and in the way in which depression itself is conceptualised. Table 1 summarises the major studies'-14 which have been conducted on depression in Parkinson's disease. Considerable variability is found between studies in the number of subjects, the nature of the samples, the methods of assessment, the criteria for diagnosis and the use of control groups. Comparison between studies is difficult because of this variability. However, a consistent finding in all of the studies which give figures, is a high rate of "depression" ranging from 20%1 to 90%,4 with a mean estimate of 46%. The validity and meaning of this estimate needs to be assessed because of its importance both to the patient and to the clinician. - One practical consideration is the population from which the patient sample was drawn. A hospitalised sample might contain patients who have suffered a sudden worsening or complication of symptoms. This may lead to a deterioration in mood that is unrepresentative of the normal mood state of the patient, or of patients not requiring hospitalisation. A direct estimation of the importance of sample selection on prevalence rates can be found from two studies which used the same diagnostic criteria on different populations. Warburton3 studied 140 hospitalised patients and found some degree of depression in 63%. Celesia and Wanamaker6 studied 153 patients at first presentation to a Parkinson's disease clinic. Some degree of depression was found, or reported for the preceding year in 37% of the cases. Furthermore, as the Celesia and Wanamaker figure was based on occurrence of depression within a 12 month period, it would have picked up many more cases than those actually depressed at the time of assessment, making the difference in depression ratio for the two studies more extreme. How many patients in these two studies would be considered to be significantly depressed by criteria such as DSM III?"
In both studies, grade I depression was described as "fleeting symptoms of depression never lasting more than 2 or 3 weeks and not severe enough to interfere with life in general". Such symptoms accounted for 7% of the Warburton sample and 12% of the Celesia 381 all of these controlled studies, whatever the criteria or method of assessment used, "depression" was significantly higher in the Parkinson's disease group than in the control group(s). This is of course different from saying that the Parkinson's disease groups were significantly depressed.
One of the most controversial issues in the relationship between Parkinson's disease and depression is the question of cause. It has been common to draw a diagnostic distinction between reactive and endogenous depression. Many studies have found high rates of depression in patients with chronic illness. Katon'9 has reviewed this matter, and reports figures of 12-25% for primary care outpatients, and 20-33% of hospital inpatients. Parkinson's disease, being a chronic and progressively disabling illness, is likely to lead to some degree of depressive reaction in a proportion of patients. However, the disease is also associated with a widespread disturbance of various neurotransmitter levels, especially dopamine but also noradrenaline and 5-hydroxytryptamine,2021 all of which have been implicated in models of depression.22 Therefore, a patient with Parkinson's disease may be depressed because of (1) disturbances in brain amine levels, (2) as a reaction to the disabling qualities of the illness, (3) both, or (4) other factors unrelated to the illness.
Some studies have sought to explore these issues by looking for associations between severity of depression and factors such as duration of illness, degree of functional disability, symptom severity and response to medication. Of the five studies which looked at duration of Parkinson's disease36812 none found significant associations with rate or severity of depression. These studies also failed to find a significant association between age and depression in Parkinson's disease. With functional disability, only one study'0 has found a significant association with depression. No association was found in the studies of Warburton,3 Horn et al,8 Robins,9 Mayeux et al'2 and Vogel et al.13 With symptom severity the situation is more equivocal. Three studies'0 12 13 found small but significant associations between symptom severity and depression, compared with four studies which did not.368 14 What are the implications of these findings for the causal models of depression in Parkinson's disease? It should be noted that both the biochemical and the reactive models predict an inverse relationship between the level of dopamine (and other monoamines) and the severity of depression. In one case this would be as a direct result of the biochemical imbalance, and in the other, this would be a response to increased symptom severity and functional disability. However, the evidence does not seem to fit either model. First, neither symptom severity, functional -disability or disease duration are consistently or strongly associated with depression, arguing against a simple reactive model or a biochemical model based upon dopamine levels. Second, levodopa seems to have little, if any, antidepressant action when given to depressives." Third, when levodopa is given to Parkinsonians, improvement in mood does not consistently accompany the significant improvement in physical symptoms.1I Fourth, traditional antidepressants which have been shown to improve the mood of patients with Parkinson's disease, have no marked effect on the patients motor state.24 Combined, this evidence suggests a dissociation between the role of dopamine and other neurotransmitters in the aetiology of depression in Parkinson's disease, and lends little weight to a simple reactive model.
The present study does not propose to answer the question of aetiology of depression in Parkinson's disease, even if a simple answer were possible. A difficulty, until now, has been the lack of detailed description on the nature of the "depressive" changes seen in Parkinson's disease. The present study aims to provide such a description. Three self-report scales were used: the Beck Depression Inventory (BDI),'8 the Beck Hopelessness Scale (HS),25 and the trait form of the Speilberger Anxiety Inventory.26 These three scales have been widely used in other clinical settings and provide detailed and reliable information on the individuals affective state. To date, only one of the scales, the BDI has been applied to Parkinson's disease12 and only then with a small sample. The present study aims to provide some detailed information in a large sample, on the nature of any depressive type changes in Parkinson's disease. Two comparison groups were used, a normal healthy age matched group and a sample of patients suffering from arthritis, a non-neurological but chronic -and disabling illness. 2 Beck Hopelessness Scale26 This is a 20 item self-rated scale. It focuses on the patient's sense of optimism/ pessimism and their expectations for the future. Each item is a statement (10 positive valence, for example "I look forward to the future with hope and enthusiasm", and 10 negative valence, for example "My future looks dark to me"), which the subject rates as "true" or "false" depending on whether the statement applies to themselves. Scores range from 0 (low hopelessness) to 20 (high hopelessness).
3 Speilberger Anxiety Index, Trait form" This is a 20 item self-rated scale. The items are descriptive statements relating to anxiety Tor example "I worry too much over something that doesn't really matter". The subject is asked to rate how well the statement describes how they feel in general. Each item is rated on a four point scale from l-"almost never" to 4-"almost always". Scores range from 20 (low anxiety) to 80 (high anxiety).
with a knife and fork" to mobility for example "get up from a chair". Subjects were asked to rate their ability to perform each activity on a 5 point scale from l-"alone without difficulty" to 5-"unable to do". To take into account fluctuations in functional ability, patients were asked to rate according to how In contrast, self-rated functional disability as measured by the ADL scale was consistently associated with the three measures, particularly for the Parkinson's disease group. Similarly, for this group, the selfrating or clinical rating of the severity of their Parkinson's disease, was significantly associated with the three measures.
Discussion
The present study provides self-report data on the affective state of an outpatient sample of patients with Parkinson's disease. On average, the Parkinson's disease group had scores indicating higher levels of 
matched, normal control group, but did not differ from a sample of patients with arthritis. The three measures employed (BDI, HS and STAI) showed high degrees of intercorrelation in all groups, so for simplicity, "depression" will be used to refer to a global affective state, including depression, anxiety and hopelessness.
Before discussing the results further, it is necessary to comment upon the response rates in the present study. The 100% response rate in the normal control group is in sharp contrast with the 47% obtained from the arthritis group. Because the normal controls were members of a volunteer subject panel, it might be argued that the high levels of motivation which this entails would bias the sample towards lower levels of depression. However, most subjects had been members of the panel for many years 
